Search Results for: "KAHR "

Investment in Israeli startups: (27/6/21)

Posted on June 27, 2021

Transmit Security raised $543 million; Lendbuzz raised $360 million; Vianai Systems raised $140 million; Firebolt raised $127 million; Hailo raised $110 million; Unit raised $51 million; JoyTunes raised $50 million; Tonkean raised $50 million; KAHR Medical raised $46.5 million; DataRails … Continue reading →

Posted in Economy & Business | Leave a comment

Cancer treatment trial extended

Posted on June 6, 2021

The Phase 1 / 2 trial of DSP107 from Israel’s KAHR Medical (see here previously) has commenced and will now be expanded to include blood cancer patients in addition to solid tumors. KAHR has received an additional investment of $5 … Continue reading →

Posted in Israel's Medical Achievements | Leave a comment

Investment in Israeli startups (30/5/21)

Posted on May 31, 2021

Global-e Online raised $375 million (IPO); Forter raised $300 million; Sunbit raised $130 million; Wiz raised $120 million; Explorium raised $75 million; Salt Security raised $70 million; Snappy raised $70 million; Rapid Medical raised $50 million; AnyClip raised $47 million; … Continue reading →

Posted in Economy & Business | Leave a comment

Approval to test treatment for advanced cancer

Posted on August 16, 2020

Israel’s KAHR Medical has received US FDA approval to begin Phase 1 & 2 clinical (human) trials of its DSP107 treatment of advanced solid tumors (reported here previously). The trials will assess DSP107 both by itself and in combination with … Continue reading →

Posted in Israel's Medical Achievements | Leave a comment

Double-whammy cancer treatment

Posted on September 22, 2019

Israel’s Kahr Medical plans to begin human trials of its DSP107 treatment on lung cancer patients. It will be tested both standalone and in combination with Roche’s Tecentriq (atezolizumab). DSP107 finds and marks cancer cells, then alerts the immune system … Continue reading →

Posted in Israel's Medical Achievements | Leave a comment

Trial of anti-lymphoma technology

Posted on September 15, 2013

Israeli biotech KAHR Medical plans to trial KAHR-102, one of its groundbreaking Signal Converting Proteins (SCP), for the treatment of lymphatic cancer. http://www.kahr-medical.com/dynamic.asp?cid=10472&ttl=strip3 http://www.globes.co.il/serveen/globes/docview.asp?did=1000878189&fid=1725 http://www.youtube.com/watch?v=pV6ibvvg5Xo

Posted in Israel's Medical Achievements | Leave a comment